LIFEVANTAGE CORP Paid-in-Kind Interest
LIFEVANTAGE CORP (LFVN) reported Paid-in-Kind Interest of $0 for the 12-month period ending 2013-06-30, per its 10-K filed 2013-09-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2013-09-12
- LIFEVANTAGE CORP paid-in-kind interest for the quarter ending 2011-06-30 was $3.10M.
- LIFEVANTAGE CORP paid-in-kind interest for the quarter ending 2011-03-31 was $1.64M.
- LIFEVANTAGE CORP paid-in-kind interest for fiscal 2013 was $0.00.
- LIFEVANTAGE CORP paid-in-kind interest for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- LIFEVANTAGE CORP paid-in-kind interest for fiscal 2011 was $4.75M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2013-06-30 | $0.00 10-K · filed 2013-09-12 | ||||
| 2012-06-30 | $0.00 10-K · filed 2013-09-12 | ||||
| 2011-06-30 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-12 | $4.75M derived: sum of 2 quarters · filed 2013-09-12 | $4.75M 10-K · filed 2013-09-12 | $4.75M 10-K · filed 2012-09-10 | |
| 2011-03-31 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-15 | $1.64M 10-Q · filed 2012-05-15 | |||
| 2010-12-31 | $108.00 10-Q · filed 2012-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |